Stay updated on Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    Change Detected
    Summary
    The value Last Update Posted (Estimated) has been changed to Last Update Posted. This change indicates that the last update posted on the webpage is now considered final and no longer estimated.
    Difference
    0.0%
    Check dated 2024-06-15T03:21:17.000Z thumbnail image
  3. Check
    2 days ago
    Change Detected
    Summary
    The study GLORIOSA has recently updated its last posted update to 2024-06-13 and the revision has changed to v2.8.1. Additionally, a new recruiting location has been added in Seattle, Washington, United States at the Swedish Cancer Institute with contact information for Antonia Truong.
    Difference
    1%
    Check dated 2024-06-14T01:54:46.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study record details of the Phase 3 clinical trial evaluating the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
    Difference
    0.0%
    Check dated 2024-06-06T15:34:58.000Z thumbnail image
  7. Check
    23 days ago
    Change Detected
    Summary
    The value (Estimated) has recently changed to . This change represents an update in the estimated completion date for the study titled 'Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA).'
    Difference
    0.0%
    Check dated 2024-05-24T04:16:41.000Z thumbnail image
  8. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect a change in the location and contact information for clinical trials. Specifically, the location 'UC San Diego Health - Moor' has been updated to 'UC San Diego Health - Moores Cancer Center' and new contact details have been provided for the Arizona location in Phoenix.
    Difference
    48%
    Check dated 2024-05-22T21:34:28.000Z thumbnail image
  9. Check
    46 days ago
    Change Detected
    Difference
    0.3%
    Check dated 2024-04-30T22:52:58.000Z thumbnail image

Stay in the know with updates to Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.